跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ISRCTN45504491
ISRCTN45504491进行中（未招募）1 期

Phase I trial, Quotient Sciences code: QSC206403 [The full scientific title will be published within 30 months after the end of the trial]

Anavex Germany GmbH0 个研究点目标入组 12 人开始时间: 2023年1月18日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
12
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •Healthy volunteer

排除标准

  • •The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

研究者

相似试验

进行中（未招募）
1 期
Phase I trial, Quotient Code: QSC208063The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
ISRCTN17473850Trevena, Inc.72
进行中（未招募）
1 期
Phase I trial, Quotient Code: QSC300720The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
ISRCTN57359805Veradermics Inc16
进行中（未招募）
1 期
Phase I Trial: Quotient Code QSC205832The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
ISRCTN16482972ovartis (Switzerland)16
进行中（未招募）
1 期
Phase I trial, Quotient code: QSC205601The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.
ISRCTN10521680ovartis (Switzerland)116
进行中（未招募）
1 期
Phase I trial: Quotient Code QSC207871The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
ISRCTN12178605ovartis Pharma AG43